Lion's Mane: Neuroplasticity in a Capsule
Most nootropics work on the same general principle: adjust a neurotransmitter system and observe the cognitive result. More acetylcholine, more dopamine, more GABA. Lion's Mane does something different. The compounds in this mushroom have been studied not for tweaking signalling chemistry, but for their relationship to nerve growth factor, a protein involved in building and maintaining the nerve cells themselves.
That distinction is why Hericium erinaceus has drawn attention from neuroscience researchers, and why an increasing number of NZ consumers are asking about it. Here is a careful, honest look at what the evidence actually shows.
What Lion's Mane Actually Is
Hericium erinaceus is an edible mushroom with a long history in East Asian culinary and traditional medicine. It grows on hardwood trees, producing a distinctive white, cascading fruiting body that earns its common name.
Beyond its culinary use, Lion's Mane contains two families of bioactive compounds that have become the focus of a growing body of research.
Hericenones are found primarily in the fruiting body (the visible mushroom). Laboratory studies identified hericenones C, D, and E as compounds capable of stimulating nerve growth factor synthesis in cell culture back in 1994 1.
Erinacines are found mainly in the mycelium (the root-like underground network). These smaller molecules have also been studied for NGF-stimulating activity and may cross the blood-brain barrier more readily than the larger hericenones 2.
This dual-compound profile is part of what makes the fruiting body versus mycelium distinction practically relevant, a point we will return to below.
The NGF Connection: Why Neuroscientists Pay Attention
Nerve growth factor (NGF) is one of the most important neurotrophins, a family of proteins that regulate the survival, development, and maintenance of nerve cells. It was the first neurotrophin discovered (by Rita Levi-Montalcini, who won the Nobel Prize for the work in 1986), and its role in neuronal health is well established.
NGF supports the maintenance of existing neurons. It promotes the growth of new neural connections, a process related to neuroplasticity. It is also involved in the survival of specific nerve cell populations, particularly in the basal forebrain cholinergic system, a region associated with memory and attention.
What makes Lion's Mane unusual among nootropics is the type of target. Rather than acting on neurotransmitter concentrations (which is what compounds like Bacopa, L-theanine, or caffeine do), its bioactive compounds have been studied for their ability to stimulate the production of a growth factor involved in neural maintenance. The mechanism is distinct.
In vitro research has demonstrated this quite clearly. Mori et al. (2008) showed that Hericium erinaceus extract increased NGF mRNA expression and NGF protein secretion in human astrocytoma cells 3. Multiple subsequent studies have confirmed this NGF-stimulating activity in cell-culture models.
The important caveat: demonstrating NGF stimulation in a petri dish is not the same as demonstrating it in a living human brain. In vitro findings generate hypotheses. Human trials test them.
What the Human Trials Show
Mori et al. (2009): The Foundational Study
The most cited clinical study on Lion's Mane is a double-blind, placebo-controlled RCT conducted in Japan. Thirty adults aged 50-80 with mild cognitive impairment were randomised to receive either Lion's Mane (four 250mg tablets three times daily, totalling 3g/day of dry powder) or placebo for 16 weeks, followed by a four-week washout period 4.
The results: participants in the Lion's Mane group showed significant improvement on a cognitive function scale (the Revised Hasegawa Dementia Scale) at weeks 8, 12, and 16 compared to placebo. Perhaps more telling, cognitive scores declined within four weeks of stopping supplementation. This pattern is consistent with what you would expect if the compound were supporting an ongoing biological process rather than producing a one-time change.
This is a well-designed study with a clear, positive result. It is also a single trial with 30 participants at one site in Japan, in a specific population (elderly with existing cognitive impairment). Encouraging, but not definitive.
Docherty et al. (2023): Acute and Chronic Effects in Young Adults
A more recent pilot study examined Lion's Mane in a different population: 41 healthy adults aged 18-45, looking at both acute effects (60 minutes after a single dose) and chronic effects (after 28 days of 1.8g/day supplementation) 5.
The acute findings were interesting. Participants performed significantly faster on the Stroop task (a test of cognitive flexibility and processing speed) 60 minutes after taking Lion's Mane. After 28 days, there was a trend toward reduced subjective stress.
However, the chronic results were mixed. The same 28-day supplementation period was associated with fewer words recalled on a delayed word recall test compared to placebo. That is not what you would hope to see in a memory study, and the researchers noted it as an unexpected finding.
The take-away: the acute cognitive findings suggest something is happening, but the full picture from this study is not uniformly positive. Honest reporting requires including the less flattering data.
Li et al. (2020): Erinacine A Pilot
A pilot double-blind, placebo-controlled study in 49 participants tested an erinacine A-enriched Hericium erinaceus mycelia preparation over 49 weeks. Participants showed significant improvements on cognitive assessment scores (CASI) and certain neurological measures 6.
This study used a specific erinacine A-enriched preparation, not a standard fruiting body extract. The results speak to that particular preparation and dose, not to Lion's Mane supplements generically.
Fruiting Body vs Mycelium: Why It Matters
This is a distinction worth understanding before choosing a product.
The fruiting body is the visible mushroom, the part that grows above the substrate. It is richer in hericenones and in beta-glucans (polysaccharides studied for immune-modulating activity).
The mycelium is the thread-like root network that grows through the substrate (often grain, in commercial production). It is richer in erinacines. However, mycelium-based products grown on grain can contain substantial amounts of the grain substrate itself, diluting the concentration of bioactive mushroom compounds.
The traditional preparation in East Asian medicine uses the fruiting body. The Mori 2009 trial used a fruiting body preparation. The Li 2020 trial used a specifically enriched mycelium preparation. Both approaches have research behind them, but the distinction matters for knowing what you are actually consuming.
SuperFeast Lion's Mane uses a single-origin fruiting body extract processed via traditional water extraction, the approach that preserves hericenone content and beta-glucan fractions. For a multi-ingredient nootropic that includes Lion's Mane alongside other cognition-studied compounds, Bader Focus is an NZ-made option.
Dosage, Timing, and What to Expect
Research doses across the human trials range from 1g to 3g of extract daily:
- Mori 2009: 3g/day of dry powder (16 weeks)
- Docherty 2023: 1.8g/day of extract (28 days)
- Li 2020: 350mg of enriched mycelia extract, three times daily (49 weeks)
The time course in the research matters for setting expectations. Mori's study showed effects emerging at 8 weeks and continuing to build through 16 weeks. This is not an acute stimulant. The decline after cessation reinforces the point: the effects appear to depend on ongoing supplementation.
Safety across the human studies has been favourable. No serious adverse events have been reported in the published trials. Lion's Mane is, after all, an edible mushroom with a long culinary history.
The Honest Caveats
An evidence-first guide requires stating what we do not yet know.
Trial sizes are small. The largest published RCT (Li 2020) enrolled 49 participants. The most cited (Mori 2009) had 30. These are pilot-scale studies, not the large, multi-site trials needed for conclusive findings.
Most mechanistic work is preclinical. The NGF stimulation story is compelling and well-supported in cell culture and animal models. Whether this mechanism translates meaningfully to the human brain at achievable oral doses has not been directly measured in published clinical work. No human study has directly assayed brain NGF levels after supplementation.
There are no long-term human studies. The longest published trial ran 49 weeks. We do not have data on years of continuous use.
Results across trials are mixed. Docherty 2023 found some positive acute effects alongside a negative finding on delayed recall. This is what early-stage research often looks like: inconsistent signals that later, larger trials may clarify.
The responsible position: Lion's Mane is one of the more interesting compounds in the nootropic space because its proposed mechanism (NGF stimulation) is genuinely novel. The human evidence is encouraging but preliminary. For someone comfortable with early-stage evidence who wants to explore a growth-factor approach alongside their existing cognition routine, it is a reasonable compound to consider. For someone who wants the large, definitive trial first, that trial has not yet been published.
For a broader view of where Lion's Mane fits in the nootropic landscape, see our Executive's Guide to Nootropics and the focus and cognition collection guide.
References
- Kawagishi H et al. "Hericenones C, D and E, stimulators of nerve growth factor synthesis, from the mushroom Hericium erinaceum." Tetrahedron Letters. 1994;35(10):1569-1572.
- Friedman M. "Chemistry, nutrition, and health-promoting properties of Hericium erinaceus (Lion's Mane) mushroom fruiting bodies and mycelia and their bioactive compounds." J Agric Food Chem. 2015;63(32):7108-7123.
- Mori K et al. "Nerve growth factor-inducing activity of Hericium erinaceus in 1321N1 human astrocytoma cells." Biol Pharm Bull. 2008;31(9):1727-1732. PMID: 18758067
- Mori K et al. "Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial." Phytother Res. 2009;23(3):367-372. PMID: 18844328
- Docherty S et al. "The acute and chronic effects of Lion's Mane mushroom supplementation on cognitive function, stress and mood in young adults: a double-blind, parallel groups, pilot study." Nutrients. 2023;15(22):4842. PMID: 38004235
- Li IC et al. "Prevention of early Alzheimer's disease by erinacine A-enriched Hericium erinaceus mycelia pilot double-blind placebo-controlled study." Front Aging Neurosci. 2020;12:155. PMID: 32581767
This article describes findings from published research for general educational purposes. It reflects what compounds have been studied for, not a promise of any individual outcome. If you take prescription medication or have a health condition, talk to a qualified healthcare professional before adding a supplement.